Novartis unveils NIBR reorganization

Novartis AG (NYSE:NVS; SIX:NOVN) unveiled details of a "realignment of resources" within the pharma's Novartis Institutes for BioMedical Research (NIBR) that is part of a new research strategy for drug discovery, spokesperson Eric Althoff told BioCentury.

The changes follow the March arrival of NIBR president James "Jay" Bradner, who told BioCentury in June he planned to experiment with open innovation models and intended to increase the number and scope of the company's research collaborations (see BioCentury Innovations, June 30). ...